Phenylketonuria Treatment Market Size, Share & Trends Analysis Report By Drug (Kuvan, Palynziq, CNSA-001, SYNB1618), By Region (North America, APAC, Europe, MEA), And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 159 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global phenylketonuria treatment market size is expected to reach USD 1.02 billion by 2026 registering a CAGR of 11.0%, according to a new report by Grand View Research, Inc. Rising prevalence of PKU across the world and favorable government regulations are the factors expected to spur the market growth over the forecast period.

For instance, according to the FDA, in 2018, phenylketonuria affected about 1 in 10,000 to 15,000 people in U.S. Furthermore, according to the Orphanet, it was estimated that 1 in 10,000 newborns in Europe is suffering from PKU. The target disease is highly prevalent in European countries, such as Italy, Ireland, and Turkey. It was estimated that around 1 in 4000 individuals in Turkey were diagnosed with PKU.

Various awareness programs conducted by private and public organizations are also projected to fuel market growth. Some of the organizations conducting such programs are SickKids, Children's Hospital of Wisconsin, CHOC Children's, and Boston Children's Hospital. These programs aim to promote optimal emotional, developmental, and physical health PKU patients.

Furthermore, continuous R&D for the disease treatment is estimated to enhance the market growth. For instance, Synlogic, Inc.'s SYNB1618 drug is undergoing Phase 1/2a clinical trials and also received fast-track designation from FDA. In addition, other companies, such as Rubius Therapeutics, Inc., Retrophin, Inc., and Homology Medicines, Inc. are also conducting research to develop novel therapies, such as oral, enzyme therapy, gene therapy.

Availability of reimbursement policies for high-cost treatments of PKU is also projected to boost the market growth. Kuvan is currently approved for use and reimbursed in many European countries, such as Germany, Belgium, France, Italy, and Austria. Furthermore, increasing number of funding programs for R&D by various organizations is anticipated to drive the market. For instance, the National PKU Alliance provides funding to research projects that helps in promoting advances in the management and treatment of PKU.

Further key findings from the study suggest:

• Kuvan held the largest market share in 2018 as it is the first and only approved drug for PKU treatment since 2007

• North America dominated the phenylketonuria treatment market in 2018 owing to the presence of well-established healthcare infrastructure, high healthcare expenditure, and favorable government regulations

• Europe region is expected to exhibit the fastest CAGR over the forecast period owing to rising R&D activities for the development of new PKU drugs

• Major companies in the market are BioMarin Pharmaceuticals, Inc.; Retrophin, Inc.; Synlogic, Inc.; Censa Phamraceuticals; Homology Medicinces, Inc.; and Rubius Therapeutics, Inc.

 Table of Contents

Chapter 1 Research Methodology & Scope
                   1.1 Information Procurement
                       1.1.1 Purchased database:
                       1.1.2 GVR's internal database
                   1.2 Research Methodology
                   1.3 Geographic scope & assumptions
                   1.4 Region-wise market calculation
                       1.4.1 Region-wise market: Base estimates
                       1.4.2 Global market: CAGR calculation
                   1.5 Region-based segment share calculation
                   1.6 List of Secondary Sources
Chapter 2 Executive Summary
                   2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
                   3.1 Market Segmentation & Scope
                       3.1.1 Market driver analysis
                           3.1.1.1 Increasing prevalence of phenylketonuria
                           3.1.1.2 Presence of pipeline drugs
                           3.1.1.3 Rising collaborations among key market players
                       3.1.2 Market restraint analysis
                           3.1.2.1 High cost of treatment
                           3.1.2.2 Stringent government regulations
                   3.2 Phenylketonuria treatment - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                   3.3 Industry Analysis - Porter's
Chapter 4 Market Categorization 1: Drug Estimates & Trend Analysis
                   4.1 Phenylketonuria Treatment Market: Drugs Movement Analysis
                   4.2 Kuvan
                       4.2.1 Kuvan market, 2015 - 2026 (USD Million)
                   4.3 Palynziq
                       4.3.1 Palynziq market, 2015 - 2026 (USD Million)
                   4.4 CNSA-001
                       4.4.1 CNSA-001 market, 2015 - 2026 (USD Million)
                   4.5 SYNB1618
                       4.5.1 SYNB1618 market, 2015 - 2026 (USD Million)
Chapter 5 Market Categorization 2: Regional Estimates & Trend Analysis, by Product & Type
                   5.1 Phenylketonuria Treatment Market Share by Region, 2018 & 2026
                   5.2 North America
                       5.2.1 North America phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.2.2 U.S.
                           5.2.2.1 U.S phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.2.3 Canada
                           5.2.3.1 Canada phenylketonuria treatment market, 2015 - 2026 (USD Million)
                   5.3 Europe
                       5.3.1 Europe phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.3.2 U.K.
                           5.3.2.1 U.K. phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.3.3 Germany
                           5.3.3.1 Germany phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.3.4 Turkey
                           5.3.4.1 Turkey phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.3.5 Ireland
                           5.3.5.1 Ireland phenylketonuria treatment market, 2015 - 2026 (USD Million)
                   5.4 Asia Pacific
                       5.4.1 Asia Pacific phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.4.2 Japan
                           5.4.2.1 Japan phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.4.3 China
                           5.4.3.1 China phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.4.4 India
                           5.4.4.1 India phenylketonuria treatment market, 2015 - 2026 (USD Million)
                   5.5 Latin America
                       5.5.1 Latin America phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.5.2 Brazil
                           5.5.2.1 Brazil phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.5.3 Mexico
                           5.5.3.1 Mexico phenylketonuria treatment market, 2015 - 2026 (USD Million)
                   5.6 MEA
                       5.6.1 MEA phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.6.2 Saudi Arabia
                           5.6.2.1 Saudi Arabia phenylketonuria treatment market, 2015 - 2026 (USD Million)
                       5.6.2 United Arab Emirates
                           5.6.2.1 United Arab Emirates phenylketonuria treatment market, 2015 - 2026 (USD Million)
Chapter 6 Competitive Landscape
                   6.1 Strategy framework
                   6.2 Market participation categorization
                   6.3 Company profiles
                       6.3.1 BioMarin Pharmaceutical Inc.
                           6.3.1.1 Company overview
                           6.3.1.2 Financial performance
                           6.3.1.3 Product benchmarking
                           6.3.1.4 Strategic insights
                       6.3.2 Synlogic, Inc.
                           6.3.2.1 Company overview
                           6.3.2.2 Financial Performance.
                           6.3.2.3 Product benchmarking
                           6.3.2.4 Strategic initiatives
                       6.3.3 Retrophin, Inc.
                           6.3.3.1 Company overview
                           6.3.3.2 Financial performance
                           6.3.3.3 Product benchmarking
                           6.3.3.4 Strategic initiatives
                       6.3.4 Daiichi Sankyo Company, Limited
                           6.3.4.1 Company overview
                           6.3.4.2 Financial performance
                           6.3.4.3 Product benchmarking
                           6.3.4.4 Strategic initiatives
                       6.3.5 Codexis, Inc.
                           6.3.5.1 Company overview
                           6.3.5.2 Financial performance
                           6.3.5.3 Product benchmarking
                           6.3.5.4 Strategic insights
                       6.3.6 SOM Innovation Biotech SL
                           6.3.6.1 Company overview
                           6.3.6.2 Financial performance
                           6.3.6.3 Product benchmarking
                           6.3.6.4 Strategic initiatives
                       6.3.7 Homology Medicines, Inc.
                           6.3.7.1 Company overview
                           6.3.7.2 Financial performance
                           6.3.7.3 Product benchmarking
                           6.3.7.4 Strategic initiatives

List of Tables

TABLE 1 North America phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 2 U.S. phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 3 Canada phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 4 Europe phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 5 U.K. phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 6 Germany phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 7 Turkey phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 8 Ireland phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 9 Asia Pacific phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 10 Japan phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 11 China phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 12 India phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 13 Latin America phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 14 Brazil phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 15 Mexico phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 16 MEA phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 17 UAE phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)
TABLE 18 Saudi Arabia phenylketonuria treatment market, by Drugs, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global phenylketonuria treatment market - Key market driver analysis
FIG. 7 Global phenylketonuria treatment market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global phenylketonuria treatment market - Porter's analysis
FIG. 10 Global phenylketonuria treatment market - PESTEL analysis
FIG. 11 Global phenylketonuria treatment market drug outlook key takeaways
FIG. 12 Global phenylketonuria treatment market: Drug movement analysis
FIG. 13 Regional market place: Key takeaways
FIG. 14 Global phenylketonuria treatment market: Regional movement analysis
FIG. 15 North America phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 16 U.S. phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 17 Canada phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 18 Europe phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 19 U.K. phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 20 Germany phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 21 Turkey phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 22 Ireland phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 23 Asia Pacific phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 24 Japan phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 25 China phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 26 India phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 27 Latin America phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 28 Brazil phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 29 Mexico phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 30 MEA phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 31 UAE phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 32 Saudi Arabia phenylketonuria treatment market, 2015 - 2026 (USD Million)
FIG. 33 Strategy framework